Clinical Trial Search

Primary: Enrollment in Diabetes Prevention or Weight Management Class (Online) — 7; 12; 39; 59 Participants — p=<0.001

Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks — -93.3; -52.4 millilitre (mL)/year (yr) — p=0.0350

Primary: Proportion of Patients Whose Quantitative Myasthenia Gravis Scores Are Increased by no More Than 3 Points at the End of the SCIg Treatment Phase — 0.864 proportion of…

Primary: Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period — 2.792; 2.779…

Primary: Six Month Progression Free Survival Rate — 8 Participants

Primary: Brief Pain Inventory Pain Severity — 5.0 units on a scale

Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…

Primary: Number of Adverse Events — 28; 31 adverse events — p=0.706

Primary: Patients Knowledge — 79; 71; 84; 75 percentage of correct answers — p=<0.001

Primary: Anthropometric Variables — 16.4; 17.0 kg/m^2 — p=0.05

Primary: Insulin Sensitivity Index (ISI) — 82.36; 80.70; 75.47; 81.54 factor — p=0.60

Primary: Percentage of Participants With Gastric Ulcer Who Had One or More Adverse Drug Reactions — 1.00 Percentage of Participants

Primary: Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure — 72.6; 54.6 percentage of participants

Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003